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Interleukin-1 (IL-1) has multiple functions in both the
periphery and the central nervous system (CNS)
and is regulated at many levels. We identified an iso-
form of the IL-1 receptor (IL-1R) accessory protein
(termed AcPb) that is expressed exclusively in the
CNS. AcPb interacted with IL-1 and the IL-1R but
was unable to mediate canonical IL-1 responses.
AcPb expression, however, modulated neuronal
gene expression in response to IL-1 treatment
in vitro. Animals lackingAcPbdemonstratedan intact
peripheral IL-1 response and developed experi-
mental autoimmune encephalomyelitis (EAE) simi-
larly to wild-type mice. AcPb-deficient mice were
instead more vulnerable to local inflammatory chal-
lenge in the CNS and suffered enhanced neuronal
degeneration as compared to AcP-deficient or wild-
typemice. These findings implicate AcPb as an addi-
tional component of the highly regulated IL-1 system
and suggest that it may play a role inmodulating CNS
responses to IL-1 and the interplay between inflam-
mation and neuronal survival.
INTRODUCTION
The interleukin-1 (IL-1) cytokines IL-1a and IL-1b induce cellular
responses through a widely expressed receptor complex
comprised of the type I IL-1 receptor (IL-1R) and the IL-1R
accessory protein (AcP) (Sims, 2002). The AcP receptor subunit
is also used by the IL-1F6, IL-1F8 and IL-1F9, and IL-33 recep-
tors (Ali et al., 2007; Chackerian et al., 2007; Palmer et al.,
2008; Towne et al., 2004). Ligation of the IL-1 receptor complex
leads to recruitment of intracellular signaling molecules medi-
ated by conserved cytoplasmic Toll-IL-1R (TIR) domains. These
signaling events underlie IL-1’s ability to regulate host defense
and tissue homeostasis in virtually every organ of the body.
The excessive or prolonged action of IL-1, however, can leadto destructive inflammation and contribute to disease. IL-1 has
been shown to play a causative or contributing role in hereditary
fever syndromes, gout, rheumatoid and systemic-onset juvenile
arthritis, and type II diabetes, and there are strong suggestions of
involvement in osteoarthritis, ischemia-reperfusion injury, neuro-
pathic and inflammatory pain, and Alzheimer disease. Conse-
quently, multiple mechanisms have evolved to regulate IL-1
activity. IL-1 is strongly induced at the transcriptional level in
response to innate inflammatory stimuli, and the processing of
IL-1b protein from precursor to active form and its secretion
from the cell are regulated processes. Subsequent to the gener-
ation of mature, active IL-1, signaling can be attenuated by an
inactive ligand analog (IL-1ra) and an inhibitory soluble receptor
(IL-1R type 2). The latter acts by decoying not only the IL-1 cyto-
kine but also the essential receptor subunit, AcP (Sims and
Smith, 2003). Here, we describe an additional, more subtle
form of regulation. We have found a splice variant of AcP, termed
AcPb, which is expressed in a CNS-specific manner and which
interferes with some, but not all, IL-1 activities and thus modu-
lates the effects of IL-1 in the brain.
RESULTS
Discovery of an IL-1R AcP Splice Isoform
with a Variant TIR Domain
We identified an open reading frame in human genomic DNA
sequence with similarity to members of the IL-1R family. Subse-
quent cloning of the full-length cDNA from both human and
mouse revealed an isoform of AcP that we have termed AcPb.
Figure 1A illustrates the alternative splicing by which the proto-
typical AcP C-terminal exon 12 is skipped and the identified
exon is utilized. Shown in Figure 1B is a sequence alignment of
the polypeptides encoded by exons 11–12 from AcP and the
AcPb isoform. The C terminus encoded by exon 12b in AcPb
has only 35% amino acid identity with that encoded by the
classic AcP exon 12. It shares motifs, however, such as box 3
(FWK) that are conserved in all TIR domains. In addition, AcPb
exon 12b encodes approximately 140 amino acids of additional
sequence C-terminal to the TIR domain that has no homology to
other protein sequences and is of unknown function.Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 817
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An AcP Isoform Regulates IL-1 in the CNSFigure 1. Genomic Organization, Sequence, and TIR Domain Structural Models of AcP Isoforms
(A) Intron-exon map of human AcP locus and alternative splicing that leads to mRNA isoforms. Shown are the translated exons (3–12) that encode the mature
AcP protein. The solid black bar indicates the extracellular exons that are deleted in the AcP-deficient animals (Cullinan et al., 1998) and the faded bar indicates
the specific exon 12b that is deleted in AcPb-deficient animals.
(B) Alignment of the alternative C termini of AcP and AcPb isoforms. Stars indicate conserved residues between human AcP and human AcPb. Specific structural
or signaling-associated motifs are indicated.
(C) Computational models of AcP and AcPb TIR domains. Structural folds of the ribbon structure are labeled according to the convention of Khan et al. (2004).
Beta sheets are indicated in yellow, alpha helices in red, and loops in blue. Shown on the bottom is the identical view with predicted surface electrostatics. Full
red is equivalent to40 kcal/mol negative charge; full blue is equivalent to 40 kcal/mol positive charge, and white is neutral charge. The arrow indicates the region
of substantial charge difference caused by the disruption of the aD helix in AcPb.818 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.
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An AcP Isoform Regulates IL-1 in the CNSCrystal structures have been determined for the TIR domains
of TLR1 and TLR2 (Xu et al., 2000) as well as the orphan IL-1R
family member IL-1RAPL (Khan et al., 2004). We used the latter
on which to model the TIR domains of AcP and AcPb and adop-
ted the same convention for annotation of secondary structure.
The AcP TIR domain (amino acids 401–553) was predicted
to contain a central 5-stranded beta-sheet surrounded by
5 alpha-helices (Figure 1C). The AcPb sequence was easily
modeled onto the same structure and was remarkably similar
to that of AcP, including conservation of the EE loop (approxi-
mately amino acids 527–534), previously implicated as an impor-
tant site for MyD88 recruitment (Li et al., 2005; Radons et al.,
2003). The only marked predicted difference between AcP and
AcPb is the disruption of the aD helix in AcPb, predominantly
because of two proline substitutions at amino acids 508 and
510. Predicted electrostatics indicated a more negatively
charged surface on the face of the AcPb TIR domain made up
of the bE strand and the DD loop-aD helix region, as a conse-
quence of the disruption of the helix (Figure 1C, bottom). Overall,
the computational modeling indicated that the AcPb cyto-
plasmic domain likely folds as a TIR domain similar to AcP, but
with one area of substantial difference.
AcPb Expression Is Restricted to the CNS
RNAexpressionprofiling demonstrated thatwhereashumanAcP
is expressed in numerous tissues, theexpressionof theAcPb iso-
form is much more restricted to tissues derived from the CNS
(whole brain, fetal brain, cerebellum, and spinal cord) and is the
more abundant isoform in these CNS tissues, with the exception
of spinal cord (Figure 2A). AcPb message was undetectable or
present at extremely low amount in multiple non-CNS-derived
cell types and in various established cell lines including those of
CNS origin, such as numerous glioblastoma and neuroblas-
toma-derived lines (not shown). Bronchial epithelial cells were
the only non-CNS sample in which AcPb mRNA was detected;
however, the expression was 1% lower than AcP mRNA and
approximately 3% of the relative amount of AcPb mRNA in total
brain RNA (not shown). The CNS-predominant expression
pattern of AcPb was also observed among mouse tissues and
cell lines (not shown). We next profiled the relative expression
of AcP and AcPb mRNA across multiple anatomical regions of
human adult brain. For comparison, the same analysis was
done formRNAs encoding both the neuron-specific gene,micro-
tubule-associated protein 2 (MAP2), and the astrocyte-specific
gene, glial fibrillary acidic protein (GFAP). AcP and AcPb have
slightly different patterns of relative brain expression (Figure 2B).
For example, AcP was much more enriched in the corpus cal-
losum than AcPb, coincident with primarily glial cell bodies in
this region. TheAcPbmRNAexpression patternwasmore similar
to that of MAP2 mRNA than that of GFAP mRNA, suggesting
a more neuronal-restricted expression pattern. RT-PCR analysis
of purified neurons, microglia, and astrocytes also indicated
a more neuron-restricted expression of AcPb mRNA, whereas
abundant AcP mRNA was detected in all three cell types
(Figure 2C and not shown). In situ RNA hybridization was used
to examine the location of expression in adult mouse brain
sections with RNA probes specific for AcP or AcPb exon 12.
AcP and AcPb mRNA displayed overlapping patterns of expres-
sion that corresponded to areas of neuronal bodies throughoutthe gray matter (Figure 2D). Collectively, these results suggest
neuronal expression of AcPb throughout the brain. The mouse
in situ hybridization data and RT-PCR results might suggest
that AcP and AcPb are coexpressed in the same cells, rather
than being expressed in different cells in the same anatomical
areas, but we have been unable to raise the appropriate anti-
bodies to prove this.
AcPb Associates with IL-1R in an IL-1-Dependent
Manner
The AcPb variant conserves the extracellular domain required for
interaction with IL-1R and IL-1, so we asked whether AcPb is
able to form complexes with the type I IL-1R in a ligand-depen-
dent manner. We utilized the IL-1R-positive, AcP-negative
mouse T cell line EL4.16a (EL4) that was stably transduced
with either a control protein (GFP) or full-length AcP or AcPb.
The surface expression of reconstituted AcP or AcPb was found
to be similar in both lines (Figure 3A). IL-1R was coimmunopreci-
pitated from both the AcP and AcPb-expressing lines but not in
the control cells that lack AcP (Figure 3B, lanes 1–3). Moreover,
the recruitment of IL-1R was dependent on ligation with IL-1 as
shown by the fact that no IL-1R band was detected in the lanes
from nontreated cells (Figure 3B, lanes 4–6). Immunoblotting
with an AcP antibody confirmed that AcP and AcPb were both
effectively immunoprecipitated even in the absence of IL-1.
These results indicated that AcPb is capable of forming
a ligand-dependent complex with IL-1R.
The proximal events that lead to IL-1-induced cellular
responses involve the recruitment of specific adaptor and
signaling molecules to the IL-1R:AcP complex. Two such mole-
cules previously shown to be crucial for elicitation of IL-1
responses are the adaptor molecule MyD88 and the kinase
IRAK4 (Burns et al., 2003; Huang et al., 1997; Jiang et al., 2003;
Wesche et al., 1997a). Immunoprecipitation experiments with
the IL-1-treated EL4 lines demonstrated that only the AcP-
expressing cells are capable of recruitingMyD88 and IRAK4 after
stimulation with IL-1 (Figure 3C). Although AcPb was able to
associate with IL-1R under these IL-1-dependent conditions, it
did not lead to the recruitment of these adaptor molecules.
AcPb Is Unable to Mediate Canonical IL-1 Signaling
Responses in EL4 Cells
Experiments were next performed to determine whether AcPb
possesses autonomous signaling capacity in response to IL-1
in the mouse EL4 cells. AcP-reconstituted, but not AcPb-recon-
stituted, cells secreted IL-2, IL-5, and IL-6 in response to IL-1
treatment (Figure 4A). In separate experiments, and consistent
with previously reported results (Wesche et al., 1997b), the
AcP-negative control EL4 cells were nonresponsive to IL-1,
demonstrating that these responses are AcP dependent (not
shown). The inability of AcPb to mediate IL-1-induced cytokine
release was next shown to correspond to an inability to activate
IL-1 signaling. IL-1 treatment led to the activation of the kinases
p38, JNK, and ERK in the cells reconstituted with AcP, but not in
the cells reconstituted with AcPb (Figure 4B). Sorbitol has previ-
ously been shown to induce p38 activation (Alpert et al., 1999)
and when used as a control stimulus, it led to activation of phos-
phorylated p38 in all three EL4 lines, indicating that AcPb expres-
sion does not lead to a general defect in cellular responsiveness,Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 819
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An AcP Isoform Regulates IL-1 in the CNSFigure 2. mRNA Expression Profile of AcP and AcPb
(A) Relative mRNA expression of AcP and AcPb isoforms in human tissues as determined by real-time PCR and presented as expression relative to HPRT.
Abbreviations: F, fetal; sm, small; sk, skeletal.
(B) Normalized relative expression of AcP and AcPb mRNAs across isolated human brain regions as compared to a neuronal- and astrocyte-specific mRNA
(MAP2 and GFAP, respectively). Relative expression (to HPRT) for each gene in each region was normalized to its overall expression in total brain (set to 100%).
(C) RT-PCR amplification of AcP and AcPb mRNAs from primary mouse hippocampal neuron and astrocyte cultures.
(D) In situ hybridization of section through the brainstem and cerebellum of adult mouse brain with RNA probes specific for AcP or AcPb isoforms. 1: whole brain
hybridized with sense strand control probe. 2: whole brain hybridized with AcP antisense probe. Cerebellum is indicated with dashed box and the brain stemwith
a solid box. 3, 4: Bright field and dark field images of cerebellum hybridized with either AcP (3) or AcPb (4) antisense probes. Positively hybridizing Purkinje cells
are indicated with an arrow for both probe sets. 5, 6: Bright field and dark field images of forebrain hybridized with either AcP (5) or AcPb (6) antisense probes.
Positively hybridizing neuronal cell bodies are visible with both probes.but rather, consistent with an inability to recruit MyD88 and
IRAK4, is unable to mediate these specific IL-1 responses.
AcPb Effects on Gene Expression in Virally
Reconstituted AcP-Deficient Cortical Neurons
We hypothesized that because the expression pattern of AcPb
suggests a centrally localized function, AcPb-dependent IL-1
responses may manifest only in a CNS-related context. For820 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.example, AcPb may utilize adaptor molecules possessing the
same restricted tissue expression as AcPb itself. We used
a primary neuron culture system to explore this hypothesis.
Cortical neuron cultures were established from C57BL/6
E17-E18 embryos and after 7–10 days the cultures were approx-
imately 70%–80% pure MAP2-positive neurons with active
neurite outgrowth (Figure 5A). Some glial cells, including
GFAP-positive cells, were also present and represented
Immunity
An AcP Isoform Regulates IL-1 in the CNSFigure 3. AcPb-Mediated IL-1R and Adaptor Recruitment
(A) AcP surface expression on EL4.16a parental and stably transfected cell lines utilizing an AcP antibody that recognizes both forms of the receptor.
(B) EL4 lines were incubated with IL-1b (100 ng/ml) for 3 min then lysed and immunoprecipitated with a pan-AcP monoclonal antibody. Precipitations were
analyzed by immunoblot (WB) via either an muIL-1R antibody or a pan-AcP antibody. Approximate molecular weights are indicated.
(C) Samples were stimulated and immunoprecipitated as in (B) and then adaptor protein recruitment was determined by immunoblot with MyD88 or IRAK4
antibodies, as indicated. Data representative of duplicate independent experiments.approximately 20%–30% of the culture. RT-PCR indicated that
IL-1R, AcP, and AcPb were all expressed in these cultures and
all seemed to increase in expression as the cultures matured
(not shown). In order to evaluate the specific contribution of
AcP (encoded by Il1rap gene) and AcPb toward responses to
IL-1, reconstitution experiments were performed with neuronal
cultures from Il1rap/ (AcP null) E17.5 embryos. The Il1rap-tar-
geted deletion eliminates two exons in the extracellular domain
of AcP (as shown in Figure 1A) and thus destroys the expression
of all functional AcP isoforms (Cullinan et al., 1998). Based on the
previously shown ability of lentivirus to infect nondividing
neurons (Blomer et al., 1997), cortical neurons from Il1rap/
embryos were transduced in triplicate with lentiviral vectors
expressing full-length AcP, AcPb, or CD25 as an unrelated
control protein. A fourth population was transduced with equal
amounts of both the AcP and AcPb vector in order to evaluate
the effect of isoform coexpression. The infection conditions
were shown to lead to vector-driven gene expression in neurons
(not shown) and we presume that cotransfection occurred at the
cellular level, but we are unable to rule out the possibility that
some cells were only transfected with either construct alone.
Two days after infection, cultures were stimulated with IL-1b
for 4 or 16 hr and total RNA was harvested. RT-PCR analysis
confirmed the reconstituted expression of specific receptor
isoforms in each population (Figure 5B). Moreover, functional
responsiveness was demonstrated by an IL-1-dependent in-
crease in Ccl2 expression in AcP-reconstituted cultures (Fig-
ure 5C).
In order to broadly survey the gene expression profiles of each
of the IL-1-stimulated populations, RNA samples were analyzed
on microarray chips containing approximately 45,000 gene
probe sets. In the Il1rap/ cultures (control virus-transduced),
when comparing untreated samples to IL-1-stimulated samples
at either 4 or 16 hr, the observed gene expression changes were
at the level of statistical noise, consistent with the AcP require-
ment for IL-1 signaling (Figure 5D). In contrast, many genes
were induced in the AcP-reconstituted cultures stimulated with
IL-1. Statistically significant (p < 0.05) gene expression ratiosfor IL-1-treated versus untreated sample sets ranged from
1- to 2-fold up to 100-fold (the limit of the analysis dynamic
range) and the specific genes regulated largely overlapped
when comparing the 4 and 16 hr data sets (not shown). There
was also substantial overlap between the IL-1-induced genes
in the AcP-reconstituted culture and genes induced by IL-1 in
a previous study with wild-type C57BL/6 cortical neurons (not
shown), suggesting that transduced AcP mediated normal
responses to IL-1 in this system. Some of the most robustly
induced genes included chemokines such as Cxcl1, Cxcl10,
and Ccl2, as well as immune-related products such as Tlr2 and
Tnfrsf12a (Table S1 available online). In contrast to the AcP-
reconstituted culture, there were no genes consistently induced
greater than 2-fold in the AcPb-reconstituted culture (Table S2).
Moreover, the few gene responses that reached statistical signif-
icance in AcPb samples were generally induced to similar levels
in the AcP-reconstituted cultures. These results indicated
that AcPb-reconstituted neuronal cultures may be capable of
a limited IL-1 signaling response, although all of the gene
responses were modest and none were unique to AcPb.
Analysis of the AcP + AcPb-reconstituted culture compared to
AcP alone indicated that AcPb coexpression was capable of
modulating AcP-dependent responses. A few genes showed
slightly increased induction in the AcP + AcPb-reconstituted
culture as compared to AcP alone, but all of the most highly
induced transcripts were induced to similar levels in the culture
with AcP alone, supporting the idea that no strong gene induc-
tion signal is specifically transduced through AcPb. Interestingly,
there were two classes of AcP-dependent gene responses:
those that were unaffected by AcPb coexpression (example:
Gbp2 fold induction at 4 hr: AcP population, 36.8, AcP + AcPb
population, 38.5) and those that were attenuated in the presence
of AcPb (example: Atf3 fold induction at 4 hr: AcP population,
22.4, AcP + AcPb population, 3.8). A summary of representative
genes in both of these classes is shown in Table 1. These results
suggest that in the context of a neuronal culture, AcPb coexpres-
sion may downmodulate some but not all AcP-dependent IL-1
responses.Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 821
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An AcP Isoform Regulates IL-1 in the CNSFigure 4. Signaling Capacity of AcPb-Reconstituted EL4 Cells
(A) EL4 lines were incubated for 24 hr in the presence of 300 ng/mL ionomycin and 100 pg/mL PMA plus or minus IL-1b (100 pg/mL), as indicated. Cytokine
concentrations in the supernatants were quantified by Luminex (bead)-based multiplex assay and all assays were performed in triplicate. Graphs show mean
plus standard deviation, n = 2.
(B) 2.03 107 cells were incubated with IL-1b (10 ng/mL) or 0.5M sorbitol at 37C for various lengths of time and lysates (approximately 0.43 106 cell equivalents/
lane) were probed by immunoblot with total and phospho-specific antibodies against p38, JNK, and ERK, as indicated. Data representative of duplicate
independent experiments.Generation of AcPb-Deficient Mice
In order to better understand the specific function of the AcPb
isoform, we generated AcPb exon 12b-deficient mice. A target-
ing vector was designed to delete only the unique exon 12b of
the AcPb isoform while leaving all of the coding exons for
classical AcP intact, as indicated in Figure 1A. Homozygous
knockout animals were generated and backcrossed completely
onto a C57BL/6 background. Expression of both AcP and AcPb
mRNA was detected in wild-type whole brain whereas, as ex-
pected, both were absent in brains from AcP-deficient animals
(Figure 6A). In contrast, only AcPbmRNAexpression was disrup-
ted in the brain of AcPb-deficient mice. At the protein level,
multiple AcP-related bands were detected in wild-type brain
by immunoprecipitation and immunoblotting, including bands822 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.corresponding to full-length AcP and the slightly larger AcPb
(Figure 6B). We also detected smaller-sized bands, possibly
corresponding to the soluble AcP mRNA variant that we have
confirmed is expressed in the brain at the RNA level (not shown);
however, proteomic analysis would be required to verify their
identity. Control immunoprecipitations were performed with
lysates from AcP- and AcPb-expressing EL4 cells. It is not clear
why the receptors did not migrate exactly as the proteins in
lysates from transfected EL4 cells, but differential glycosylation
may underlie some of this difference. The larger AcPb-sized
band was uniquely absent in the brains from AcPb-deficient
mice, indicating that the exon 12b deletion resulted in loss of
this isoform but did not interfere with protein expression of the
other forms of AcP.
Immunity
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normal. Staining of brain sections from 8-week-old AcP- or
AcPb-deficient mice with Weil (to reveal myelin) and Thionine
Nissl (to reveal cell bodies) did not reveal obvious abnormalities
as compared to age- and gender-matched wild-type controls
(Figure 6C). We next demonstrated that peripheral responsive-
ness to IL-1 was still intact in AcPb-deficient mice. IL-6 induction
in response to IL-1 was observed in splenocyte cultures from
three independent mice from both wild-type and AcPb-deficient
colonies (Figure 6D). In contrast, IL-1 was unable to induce IL-6
secretion from AcP-deficient splenocytes (p < 0.01), consistent
with previous findings (Cullinan et al., 1998). All three cultures
responded to LPS stimulation, indicating that cells from both
knockouts were still responsive to an alternative form of activa-
tion. Taken together, our results indicate that the AcPb exon
12b deletion selectively ablated the AcPb isoform while main-
taining classic AcP expression and function.
Figure 5. IL-1-Induced Responses in Pri-
mary Cortical Neurons
(A) C57BL/6 embryonic cortical neuron cultures
were stained by immmunohistochemistry after
9 days of culture with antibodies that recognize
either the neuronal-specific protein MAP-2 or the
astrocyte-specific protein GFAP, as indicated.
(B) RT-PCR demonstrating specific expression of
specific AcP isoforms in lentiviral vector-trans-
duced neuronal cultures but not in nontransduced
AcP/ culture 2 days after transduction.
(C) RT-PCR detection of Ccl2 transcript in trans-
duced neuronal cultures stimulated for 4 or 18 hr
with IL-1b (10 ng/mL), as indicated.
(D) Gene intensity profiles of AcP-deficient and
AcP isoform-reconstituted neuronal cultures
(as indicated) stimulated with IL-1b (10 ng/mL)
for 4 hr. RNA samples were used to hybridize
a 45,000 probe set microarray as described in
the Experimental Procedures. Immunohistochem-
istry images representative of several independent
cultures and microarray experiment performed
once with triplicate stimulations for each cell
population.
Effects of Pan-AcP and
AcPb-Specific Deletion in Models
of CNS Inflammation
We examined the effect of complete AcP
deficiency versus AcPb-specific deletion
in two different models of immune-
mediated CNS pathology. First, we eval-
uated bothmutant strains in experimental
autoimmune encephalomyelitis (EAE), a
model of peripherally induced autoim-
mune-mediated CNS disease. Subcuta-
neous immunization with MOG35-55 in
CFA resulted in 100% disease incidence
in wild-type C57Bl/6 mice (Figure 7A). In
contrast, AcP-deficient mice were almost
completely protected from disease with
only 5% incidence (1 of 18 mice) and
significantly less weight loss and lower
clinical score compared to wild-type mice (Figures 7A–7C).
AcPb-deficient mice, however, had disease onset and incidence
(Figure 7A) and disease progression (Figures 7B and 7C) similar
to that of wild-type controls. Nevertheless, 11 days after immu-
nization, the AcPb-deficient mice did have a statistically signifi-
cant increase in weight loss compared to wild-type controls
(p < 0.05) (Figure 7B). WemeasuredmRNA expression of several
inflammatory mediators in the spinal cords of naive mice and
mice at 20 days after immunization. MOG35-55 immunization
led to significantly elevated amounts of IL-1b and TNF mRNA
in the spinal cords of wild-type mice compared to naive animals
(Figure 7D). IL-1b and TNF were comparably increased in the
spinal cords of immunized AcPb-deficient mice, but not in
AcP-deficient mice, compared to the respective naive controls,
and these results correlated with the disease status. We also
observed evidence of T cell-driven CNS inflammation, includ-
ing increased amounts of the mRNA for Th1-associatedImmunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 823
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An AcP Isoform Regulates IL-1 in the CNSTable 1. Two Classes of AcP-Dependent Responses
Gene Name Accession # AcP (p value) AcP+AcPb (p value)
AcP-Dependent Responses Unaffected by AcPb Expression
Gbp2 NM_010260 36.8 ± 13% (0.0) 38.5 ± 22% (8.0E-24)
Ccl2 NM_011333 14.1 ± 19% (2.2E-17) 13.6 ± 14% (6.2E-27)
Cxcl2 NM_009140 13.6 ± 21% (5.4E-14) 12.7 ± 29% (3.0E-08)
Ptx3 NM_008987 11.7 ± 9% (0.0002) 11.9 ± 13% (0.0004)
Cxcl5 NM_009141 10.0 ± 27% (2.5E-07) 8.8 ± 22% (5.4E-09)
Egr2 NM_010118 8.8 ± 14% (2.0E-28) 8.1 ± 13% (2.8E-31)
Tlr2 NM_011905 5.2 ± 13% (7.9E-14) 5.0 ± 14% (5.9E-10)
AcP-Dependent Responses Attenuated by AcPb Expression
Atf3 NM_007498 22.4 ± 37% (1.6E-08) 3.8 ± 19% (0.00005)
Tnfrsf12a NM_013749 39.3 ± 50% (1.3E-12) 1.9 ± 29% (4.3E-08)
Cebpd NM_007679 12.7 ± 9% (0.0) 4.1 ± 14% (1.8E-08)
Cp NM_001042611 10.1 ± 14% (5.1E-20) 2.5 ± 22% (0.01)
Fos NM_010234 2.9 ± 7% (2.2E-13) 1.5 ± 7% (0.0008)
Fold-change induction for each gene was measured in a ratio between sets of chips from triplicate samples of unstimulated and IL-1b-stimulated
neuronal cultures with the Resolver log error converted to an average percentage. The p value in parentheses is evaluated for the null hypothesis
of no change because of stimulation and is uncorrected for multiple testing. The second column is the IL-1 induced fold-change in AcP-deficient cells
transduced with only the AcP vector, whereas the third column is for cells transduced with both AcP and AcPb vectors.transcription factor T-bet and the effector cytokine IL-17A, in
immunized wild-type and AcPb-deficient mice but not the AcP-
deficient mice, compared to naive mice. Taken together, these
results indicate that the absence of AcP is associated with
profound protection from EAE, whereas loss of AcPb does not
confer the same protection.
Innate immune activation in the brain is not itself detrimental
but can lead to neurotoxic consequences if not adequately regu-
lated, such as, for example, in the context of glucocorticoid
blockade. In such a model, it has been shown that the ensuing
neurodegeneration in response to a single intracerebral bolus
of LPS is in part dependent on IL-1, suggesting that in the
absence of sufficient regulation of IL-1 activity, signaling can
lead to neuronal loss (Nadeau and Rivest, 2003). We used this
experimental system to determine whether the regulatory effect
of AcPb expression is associated with neuroprotection in the
context of a local inflammatory response. LPS was infused into
the brains of wild-type, AcP-, or AcPb-deficient mice (3–4
mice/group), and subsequent inflammatory response and
neuronal damage was assessed by in situ hybridization for
expression of IL-1b and themyelin constituent PLP, respectively,
or by Fluoro-Jade (FJB) staining of degenerative neurons.
Consistent with previous findings, LPS was shown to induce
an inflammatory response in the brain as evidenced by induction
of IL-1bmRNA within 24 hr, which was similar in all three lines of
mice (Figure 7E). IL-1b mRNA was undetectable in the saline-
treated animals (not shown). As shown in Figures 7F–7H, LPS
administration did not lead to observable demyelination or
neuronal loss in either wild-type or AcP-deficient animals. In
contrast, at day 3, AcPb-deficient mice exhibited a clear and
localized loss of expression of the myelin constituent PLP that
was near, but distinct from, the LPS injection site. This decrease
in PLP mRNA expression was frequently associated with
a concomitant neurodegeneration, demonstrated by FJB-bright
neuronal bodies at the site of PLP loss in AcPb null brains. The824 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.physical injury of the needle also induced some FJB-positive
neurons near the injection tract in both saline- and LPS-treated
groups of all mice; however, FJB-positive neurons were found
far from the injection site only in the brains of all AcPb-deficient
mice challenged with LPS and none of the wild-type or AcP-defi-
cient mice. Interestingly, the LPS-induced neuronal loss in AcPb
mice was not yet detectable at 24 hr (not shown), suggesting that
it was not an immediate consequence of LPS administration.
These results indicate that AcPb can play an important role in
neuro-protection during an acute inflammatory response in the
CNS, possibly by regulating the activity of IL-1.
DISCUSSION
IL-1 and the IL-1 receptors are expressed in the brain, and IL-1 is
known to regulate a number of adaptive physiologic processes in
the CNS, including sickness behavior (Konsman et al., 2002),
fever response (Dinarello, 2004), and activation of the pituitary-
adrenal axis (Besedovsky et al., 1986). Many of these activities
are thought to result from direct effects of IL-1 on neuronal cells.
IL-1 expression in the brain is usually low and exogenous IL-1 is
not itself toxic to neurons when administered acutely into the
healthy brain. Cellular responses to IL-1 are modulated by the
physiologic state, however, and under various pathological
conditions IL-1 has been shown to exacerbate neurodegenera-
tion, for example, in response to traumatic brain injury, seizure,
or acute ischemic insult (reviewed by Bartfai et al., 2007;
Rothwell et al., 1997). Unregulated IL-1 activity has also been
implicated in mental retardation associated with multisystem
inflammatory disease (Goldbach-Mansky et al., 2006). The
mechanisms by which IL-1 influences these centrally mediated
effects are likely to be complex and may involve, in part,
neuronal-specific signaling (Davis et al., 2006; Pizzi et al.,
2002; Srinivasan et al., 2004; Tsakiri et al., 2008). The existence
and structure of the AcPb molecule suggests that it could play
Immunity
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CNS.
AcPb was recruited to ligand-bound IL-1 receptor in similar
fashion to AcP and we presume that AcPb can also be recruited
to other AcP-utilizing receptors such as ST2 (Ali et al., 2007;
Chackerian et al., 2007; Palmer et al., 2008) and IL-1Rrp2 (Towne
et al., 2004) once they have bound their ligands. IL-1Rrp2 was
initially cloned from brain (Lovenberg et al., 1996) and ST2
mRNA is found in the CNS (unpublished observations and Andre
et al., 2005), so the functions of these two receptors and their
ligands IL-33 and the IL-1F proteins may also be modified by
AcPb. AcPb does not permit the recruitment of key signaling
molecules or the elicitation of canonical signaling responses
whether either IL-1a or IL-1b is used or when AcPb is coex-
pressed with chimeric receptors containing the cytoplasmic
domains of other IL-1R family members (not shown); thus the
signaling function, if any, of AcPb is considerably different from
that of AcP. It is likely that the inability to recruit key signaling
Figure 6. Generation of AcPb Knockout
Mouse
AcPb-deficient (KO) animals were generated as
described in the Experimental Procedures and as
indicated in Figure 1.
(A) RT-PCR primers specific for AcP, AcPb, or
HPRT (as a control) were used to amplify cDNA
generated from whole brain tissue from wild-
type, AcP-deficient, or AcPb-deficient mice.
Plasmid DNA for each cDNA was used as positive
PCR controls and H2O as a negative PCR control.
Data representative of at least three mice per
genotype.
(B) Immunoprecipitations of AcP- and AcPb-EL4
cell lysates or whole brain lysates from wild-type
or AcPb-deficient mice were performed with
a pan-AcP antibody and analyzed by immunoblot
with a polyclonal AcP antibody, as described in the
Experimental Procedures. Data representative of
duplicate independent experiments.
(C) Brains were collected from 10-week-old mice
and coronal plane sections were stained with
Thionine- Nissl to reveal cell bodies and general
morphology. Images are indicative of observa-
tions across the interval of sections. Data
representative of three age-matched mice per
genotype.
(D) Splenocytes were isolated from wild-type,
AcP-deficient, or AcPb-deficient mice and
stimulated with IL-1b at the indicated concentra-
tions. Supernatants were collected for determina-
tion of IL-6 concentrations after 48 hr. Graph
shows mean ± SEM, n = 2 and results were gener-
ated with splenocytes from three individual mice
per genotype and average fold induction is
indicated (N.S. = not significant, **p < 0.001).
components to the receptor and promote
cytokine induction is due to the changed
configuration in the DD loop and aD helix
regions of the AcPb TIR domain and to
the altered charge distribution pattern
on its surface, both of which could affect
interaction with other proteins. It is inter-
esting to note that SIGIRR, another TIR domain-containing trans-
membrane protein postulated to play a negative role in IL-1 and
TLR signaling (Garlanda et al., 2007; Qin et al., 2005; Thomassen
et al., 1999; Wald et al., 2003), also has several prolines in the
same region as those which disrupt the aD helix in AcPb.
In contrast to AcP, introduction of AcPb into neuronal cultures
derived from mice deficient in all splice forms of AcP led to only
a low-level induction of a limited set of genes, of perhaps ques-
tionable significance. This result indicated that even if AcPb
interacts with novel cofactors or utilizes distinct signal transduc-
tion pathways, it is still unable to mediate a robust IL-1 response
at the level of gene induction. In the context of AcP and AcPb
coexpression, genes induced by IL-1 fell into one of two cate-
gories. Some genes (e.g., Gbp2, Ccl2, and Cxcl2) were induced
as strongly in coexpressing cells as in cells expressing only AcP.
Expression of other genes (e.g., Atf3, Icam1, and Cebpd),
however, was dramatically inhibited when AcPb was coex-
pressed with AcP. Thus, consistent with its retention of a variantImmunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 825
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Female C57Bl/6 wild-type, AcP-deficient (AcP KO), or AcPb-deficient (AcPb KO) mice (approximately 10 weeks old) were immunized s.c. with MOG35-55 in CFA
on day 0 to induce experimental autoimmune encephalomyelitis. Pertussis toxin (350 ng/mouse) in PBS was injected i.v. 48 hr after immunization. Animals were
monitored, weighed, and scored for clinical disease every other day until disease was observed, then daily thereafter.
(A) Disease incidence (p < 0.0001, Logrank test).
(B) Change in weight (p < 0.05, one-way ANOVA, Tukey’s post hoc test).
(C) Clinical score.
(D) RNA was extracted on day 20 after immunization from spinal cords of mice from each strain as indicated and gene expression was profiled by real-time PCR.
Gene expression relative to HPRT is plotted for each gene as mean ± SEM. Experiment performed once with 5 mice per genotpye.826 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.
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rather changes the quality of the IL-1 response by skewing the
gene expression pattern. Another report has described this
same splice variant of AcP (Lu et al., 2008), but the results
reported in that manuscript for the effect of the AcP variant on
gene expression differ from ours. We do not know how to explain
the discrepancy except that their conclusions were drawn
predominantly from overexpression studies in HEK293 cells.
It was previously reported that IL-1R deficiency protects mice
from Th17 cell-mediated inflammation and CNS damage in
a model of EAE (Sutton et al., 2006). Consistent with these
findings, we observed a profound protective effect of AcP defi-
ciency in EAE; however, the loss of AcPb conferred no such
protection compared to wild-type controls, possibly reflecting
the contribution of a peripheral immune compartment in this
model. Inhibition of IL-1 directly in the CNS has been shown by
others to be beneficial in EAE; however, this may have been
due to inhibiting actions of IL-1 on non-AcPb-expressing cells
(Furlan et al., 2007). In an acute model of local LPS challenge
in the CNS, the absence of AcPb expression led to neuronal
loss in response to an otherwise nontoxic innate immune stimu-
lation. This in vivo result indicated that, possibly by modulating
the intracellular signaling and gene expression response to
LPS-induced IL-1, AcPb expression may buffer the neurotoxic
effects of IL-1 or possibly the other AcP-utilizing cytokines. Inter-
estingly, the transcription factor ATF3, one of the IL-1-induced
genes whose induction was dramatically reduced by AcPb
coexpression in our neuronal culture, has been implicated in
mediating neurodegeneration in various experimental settings
(Chen et al., 2008; Song et al., 2008). In light of this finding, it
will be interesting to further investigate how different environ-
mental and pathologic conditions modulate the relative expres-
sion of AcP and AcPb, because their ratio could determine
neuronal outcome in settings that involve excess IL-1 activity.
The presence of AcPb extends the range of regulatory mech-
anisms used to control IL-1 activity. In addition to the blockade of
the type I IL-1 receptor by IL-1ra and the decoy function of either
membrane-bound or soluble type 2 IL-1R, there are now three
regulatory complexes involving the accessory protein. Soluble
AcP greatly enhances the ability of soluble type 2 IL-1R to inhibit
IL-1 action (Smith et al., 2003), and on the cell membrane, full-
length type 2 IL-1R bound to IL-1 decoys not only the ligand
but also AcP away from productive interaction with IL-1 bound
type 1 IL-1R (Lang et al., 1998; Malinowsky et al., 1998). There
is also an inhibitory activity of soluble AcP alone although the
mechanism has not been biochemically defined (Smeets et al.,
2005). In contrast to these forms of regulation, only certain IL-1
responses are inhibited by AcPb. Thus, rather than eliminating
an IL-1 signal entirely, the quality of the signal is altered. One
hypothesis for the selective inhibitory effect of AcPb is that it
generally inhibits all IL-1 responses in an AcP-competitivemanner through a failure to recruit MyD88 and IRAK4, and that
the effect on expression of particular genes is determined by
the overall strength of signal required for induction of each
gene, such as previously described for Erk-dependent activation
of IL-1 and TNF genes (Papoutsopoulou et al., 2006). Our prelim-
inary experiments do not support this hypothesis. Another expla-
nation would be that AcPb initiates a signaling function that is
insufficient for gene induction on its own, but might be required
for full induction of some genes, possibly in association with
novel adaptor proteins expressed in the brain (Kim et al., 2007;
Su et al., 2007). A third possibility is that the functional IL-1
receptor complex contains multiple IL1R and AcP molecules,
and if AcPb as well as AcP is part of the complex but is unable
to recruit MyD88, the stoichiometry of the signaling complex
would be altered.
In addition to its altered TIR domain, AcPb differs from AcP in
that it contains a C-terminal ‘‘tail’’ of approximately 140 amino
acids. C-terminal tails are also found in the IL-1R familymembers
SIGIRR, TIGIRR, and IL-1RAPL (TIGIRR-2); however; the amount
of sequence identity among them is low and none are homolo-
gous to the AcPb sequence. Although this has obvious implica-
tions for regulation of signaling, we have found that the presence
or absence of the C-terminal tail does not affect the inability
of AcPb to mediate IL-1-IL-1R signaling (not shown). The
C-terminal tail could of course mediate a function entirely inde-
pendent of IL-1 signaling. In the case of the X-linked receptor
family member APL, which is genetically associated with cogni-
tive function and autism in humans, the C-terminal extension is
reported to interact with neuronal calcium sensor-1 and regulate
neuron growth (Bhat et al., 2008; Gambino et al., 2007; Gao et al.,
2008; Piton et al., 2008; Tabolacci et al., 2006). The C-terminal
extension of AcPb offers the opportunity to interact with other
proteins, recruiting them to the receptor complex or perhaps
affecting the cellular location of the complex.
EXPERIMENTAL PROCEDURES
cDNA Cloning
A computational search for novel sequences with similarity to members of the
IL-1R family was applied to human genomic DNA sequence (Celera human
genome assembly R23- sequence CRA27000022534528). An open reading
frame was identified on chromosome 3q28 that was 31% identical to exon
12 of IL-1RAcP. 50 RACE and PCR were used to clone full-length AcPb
sequence from human cDNA libraries. An orthologous AcPb exon 12was iden-
tified in mouse genomic sequence that is 92.4% identical to the human exon
at the amino acid level and full-length AcPb cDNA was cloned from mouse
total brain.
PCR
First-strand cDNA from multiple human and mouse tissues was amplified
by real-time PCR via Taqman primer and probe sets specific for AcP or
AcPb. The sequences of the primers and probes are as follows (50 to 30).
Human AcP: primer 1 (GGGCAGGTTCTGGAAGCA) at 900 nM, primer 2(E) Mice (approximately 10 weeks old) were anesthetized and 1 ml of LPS (1 mg/ml) was injected intracerebrally over a 1 min period. 3 days later, mice were deeply
anesthetized and perfused, and fixed brains were collected and processed as described in the Experimental Procedures. IL-1b mRNA was quantified after
LPS administration by in situ hybridization. OD = optical density of IL-1b signal on radiographic film (not shown).
(F) Proteolipid protein (PLP) in situ hybridization (black and white image) and Fluoro-Jade B (FJB) staining (cell bodies of degenerating neurons stain green)
of brains 3 days after LPS administration. White dashed lines indicate location of injection tract and red dashed boxes indicate regions of localized PLP loss
and FJB-positive neurons (also shown at 2003 magnification from AcPb brain).
(G and H) The relative area of lost PLP expression (G) or the number of FJB-positive degenerating neurons (H) were quantified by ImageJ software and results are
expressed as mean ± SEM (*p < 0.05, ***p < 0.001). Data are representative of brains from either 3 or 4 individual mice per treatment group.Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc. 827
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TGGCCACCTGCAG) at 200 nM. Human AcPb: primer 1 (TCCAAGCACCGAG
GGAAGT) at 900 nM, primer 2 (AGGTGATTCTCTCCTTCACAGTAGGT) at
900 nM, and FAM probe (CCGCCACCTGCCGCTGTTG) at 200 nM. Mouse
AcP: primer 1 (GGGCAACATCAACGTCATTTT) at 300 nM, primer 2 (CAGCTC
TTTCACCTTCATGTCCTT) at 50 nM, and FAM probe (CACAGCTTTGTACTGC
ACT) at 200 nM.Mouse AcPb: primer 1 (GGAGTTTAAGCTGGGTGTCATGT) at
50 nM, primer 2 (TGCTCAAGCGGACGGTACT) at 50 nM, and FAM probe
(CCATTGCCACTAAGC) at 200 nM. All reactions were run in triplicate, and
Ct (threshold) values to determine relative expression were normalized against
the housekeeper gene HPRT. cDNAs from pooled human brain regions were
obtained from Clontech. Real-time PCR profiling of spinal cord tissue from
mice with EAE was performed with a custom Taqman Low density Array
(Applied Biosystems). For RT-PCR analysis of AcP and AcPb expression in
cultured cells, day 16 embryonic mouse hippocampal neurons and astrocytes
were cultured as previously described (Srinivasan et al., 2004). Total RNA was
isolated with trizol reagent (Invitrogen) as recommended by the manufacturer
and 1 mg of reverse-transcribed cDNA was amplified for 35 cycles with the
following primers: AcP (mAcP.cyto.foward 50-TGTTTCCTATGCAAGAAATGT
GGAAGAAGAGG-30, mAcP.cyto.rev: 50-TGCTTGTCATTGCTAGACCACCTG
G-30) and AcPb (mAcP.cyto.foward: 50-TGTTTCCTATGCAAGAAATGTGGAA
GAAGAGG-30, mAcPb.1.rev: 50-ATGGGGTTGCTCAAGCGACGGTACTCCA
C-30 ). PCR products were resolved on a 1% agarose gel and stained with
ethidium bromide.
In Situ Hybridization
Antisense 35S-UTP riboprobes specific for mouse AcP or AcPb mRNAs were
made with RNA polymerase reactions with linearized plasmids containing
either mouse AcP exon 12 or AcPb exon 12. Adult mouse brain sections
were hybridized and exposed to radiographic emulsion for 5 or 12 days. As
a control, sense strand riboprobe hybridizations were performed. Sections
were stained with hematoxylin and eosin for bright field images.
Computational Modeling
The models of AcP and AcPb TIR domains were built based on alignments to
the crystal structure of the Toll/Interleukin-1 receptor (TIR) domain of human
IL-1RAPL (Khan et al., 2004), PDB id 1T3G, chain A. The protein structure
models were built via the Homology Modeling method within the Molecular
Operating Environment (MOE, Chemical Computing Group, Montreal,
Quebec, Canada).
EL4 Stable Lines
EL4.16a cells (IL-1R+/AcP mouse lymphoma line) were transduced with
retroviral vectors (Amgen, Inc.) encoding full-length muAcP or muAcPb
and selected by FACS sorting for positive surface expression of the AcP extra-
cellular domain with M215 antibody (rat IgG, Amgen Inc.). For immunoprecip-
itation experiments, 3 3 107 cells were incubated with or without IL-1b
(100 ng/mL) at 37C for 3 min. Whole-cell lysates were immunoprecipitated
with the M215 antibody then subjected to SDS-PAGE. Coprecipitation of
IL-1R or signaling molecules was evaluated by western blotting with anti-
muIL-1R, anti-MyD88, or anti-IRAK4 polyclonal antibodies (P2, Amgen Inc.,
Chemicon #16527 or #16529 and Cell Signaling Technologies #4363, respec-
tively). For IL-2, IL-5, and IL-6 measurements, 0.253 106 cells were incubated
in triplicate for 24 hr in the presence of 300 ng/mL ionomycin and 100 pg/mL
PMA (both from Sigma) plus or minus IL-1b (100 pg/mL). Cytokine levels in
the supernatants were quantified by Luminex-based multiplex assay (Luminex
Corp.) with reagents from Biosource International. To measure induction of
phosphorylated kinases, 2.0 3 107 cells were incubated with or without IL-1b
(10 ng/mL) or 0.5 M sorbitol at 37C for various lengths of time and then imme-
diately lysed. Equivalent amounts of lysates (approximately 0.4 3 106 cell
equivalents/lane) were subjected to SDS-PAGE and western blotting was per-
formed with phospho-specific antibodies phospho-p44/p42 (Cell Signaling
Technologies #9101), phospho-JNK (Cell Signaling Technologies #9251),
and phospho-p38 (Cell Signaling Technologies #9211).
Animals Used and Description of AcPb Knockout Mice
Homozygous AcP-deficient mice (B6;129S-Il1rap) were obtained from
Taconic Laboratories and were completely backcrossed onto a C57BL/6Tac828 Immunity 30, 817–831, June 19, 2009 ª2009 Elsevier Inc.background as confirmed by microsatellite analysis (performed by Charles
River Laboratories). AcPb knockout mice (B6;129-Il1racpb) were generated
utilizing a 10.6 kb targeting cassette that replaced the entire AcPb-specific
exon 12 with a neomycin resistance gene (as shown in Figure 1). The upstream
exon 12 of classic AcP and the intervening 7.3 kb intron were left intact in order
to maintain expression of normal full-length AcP. 129 embryonic stem (ES)
cells were transfected with the targeting vector and selected under standard
conditions. ES cell clones were transplanted into Black-Swiss females and
homozygous animals were backcrossed completely onto a C57BL/6Tac back-
ground, as confirmed by microsatellite analysis (performed by Charles River
Laboratories). Il1racpb mice bred normally and appeared phenotypically
normal. Wild-type and knockout mice were subsequently obtained from
Taconic Labs, where they were maintained under standard germ-free barrier
conditions. All animal studies were reviewed and approved by the Amgen
Animal Care and Use Committee or were conducted according to the
Canadian Council on Animal Care guidelines, as administered by the Laval
University Animal Welfare Committee.
Cortical Neuron Cultures
Pregnant mice (E17–E18) were anesthetized by CO2 and brains were surgically
removed. Microdissected cortical tissue was digested for 45 min at 37C in
papain solution (Worthington Biochemical) then gently disassociated in
DMEM + 10% FBS with a 10 ml pipette followed by gentle filtration through
a 40 mm cell strainer. Single-cell suspensions were plated into 6-well tissue
culture dishes precoated with 0.1 mg/ml Poly-L-Ornithine (Sigma) and placed
in a 37C incubator with 5% CO2 (approximately 1 3 10
6 cells/well). 30 min
later, the medium was replaced with serum-free neuronal growth medium
(2% B-27 supplement + 1% PSG in Neurobasal Medium [Invitrogen Corp])
and cultures were maintained for 9 days to allow for neuronal maturation.
For immunostaining, cells were fixed for 15 min with 2% paraformaldehyde
then permeabilized with 0.1% Triton. Cells were blocked with SuperBlock
(Pierce) and 2.5% normal horse serum (Hyclone) for 1.5 hr then incubated
with primary antibodies diluted in TBS + 1% horse serum + 0.05% Tween-
20. For neuronal staining: anti-MAP-2 (Chemicon Ab5622), for glial cell
staining: anti-GFAP (Chemicon MAB3402). Staining was completed with
NovRed substrate and reagents from the Vectastain ABC peroxidase system
(Vector Laboratories). AcP or AcPb expression and induction of CCL2 mRNA
was determined by RT-PCR analysis of total RNA.
Microarray Analysis
Cortical neuron cultures were established from homozygous AcP-deficient
mice (B6;129S-Il1rap) (Cullinan et al., 1998) as described above. After
7 days of culture, cells were transduced at an MOI of 5 with lentivirus vector
(pLV401, Amgen Inc.) engineered to express either a cytoplasmic domain-
truncated form of IL-2Ra (CD25, control) or full-length muAcP or muAcPb.
After incubation for 2 hr at 37C, cells were washed with PBS and placed
back in Neurobasal growth medium and cultured for 2 days. On day 9, cells
were left untreated or stimulated in triplicate with IL-1b (10 ng/mL) for either
4 or 16 hr and then collected for total RNA preparation. Receptor expression
and Ccl2 induction was confirmed by RT-PCR and for microarray analysis,
individual biological replicate RNAs were separately labeled and hybridized
to Affymetrix Mo430 microarray chips containing approximately 45,000 probe
sets (Affymetrix). Data from individual arrays were first normalized then
compared as ratios between sample sets at the level of the reporter probes,
generating an error-weighted gene expression ratio via the Resolver software
system (Rosetta Biosoftware). Sequences with high noise between replicate
experiments were filtered out, and expression changes were calculated with
the Resolver ‘‘Affymetrix with Reporters’’ error model. Relative error was
calculated in logarithmic space and converted to amean error in Fold-Change.
Characterization of Mutant Mice
To examine the expression of AcP and AcPb in mutant mice, whole brains
were isolated from wild-type, AcP-deficient, and AcPb-deficient animals and
total RNA was evaluated by RT-PCR amplification of AcP, AcPb, and the
control gene HPRT. Phenotypic analysis of age-matched brains was assessed
by Weil and Thionine staining to reveal cell bodies and myelin, respectively
(Neuroscience Associates, Knoxville, TN). In brief, brains were perfused,
embedded, and sectioned at 35 mm in the coronal plane through the entire
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ness of peripheral cells to IL-1b, spleens were harvested from individual
C57Bl/6, AcP-deficient, and AcPb-deficient mice (n = 3/group) and RBC-free
single cell cultures were established. Cells were left untreated or stimulated
with hIL-1b (at 0.4 or 4.0 ng/ml) or LPS (10 ng/ml). Supernatants were collected
48 hr later and the concentration of IL-6 produced was determined by ELISA
(R&D Systems). To examine expression of AcP protein isoforms in total brain,
protein lysates were generated by homogenization of brain tissue in TPER lysis
buffer (Pierce) via a TissueLyzer system (QIAGEN). Cleared lysateswere immu-
noprecipitated at 4C with anti-muAcP (M215) and proteins were subjected to
SDS-PAGE, transferred to nitrocellulosemembranes, and incubated overnight
with a rabbit polyclonal antibody against muAcP that detects both AcP and
AcPb (P2, Amgen Inc.). Similar M215 immunoprecipitations of AcP and AcPb
from stable EL4 cell lines (described above) were included as controls on the
gel. In brief, lysateswere generated from100million cells in 3.2ml of lysis buffer
andAcPandAcPbwere immunoprecipitated from1ml of lysateduring an over-
night incubation at 4C with the M215 Ab, as above. Immunoprecipitated
proteins, corresponding to approximately 6 million cell equivalents, were
analyzed by immunoblot alongside the brain immunoprecipitations.
EAE
To induce EAE, 10-week-old female C57Bl/6 (n = 15), AcP-deficient (n = 18),
and AcPb-deficient (n = 14) mice were immunized s.c. with 150 mg myelin
oligodendrocyte glycoprotein amino acids 35–55 (MOG35-55; Amgen Inc.,
Seattle, WA) in an emulsion with CFA (Sigma, St. Louis, MO) containing
400 mgM. tuberculosis H37 Ra (Difco Lawrence, KS) on day 0. Pertussis toxin
(350 ng/mouse) in PBSwas injected i.v. 48 hr after immunization. Animals were
monitored, weighed, and scored for clinical disease every other day until
disease was observed, then daily thereafter. Disease onset was defined as
a score of 1 or more for more than two successive days. EAE scoring was
performed as follows: 0, no abnormality; 1, a limp tail; 2, impairment of righting
reflex or abnormal gait; 3, severe hind limb weakness, partial hind limb paral-
ysis; 4, complete hind limb paralysis, mobile by use of forelimbs. Mice were
euthanized on day 20 after immunization. Spinal cords from 5 naive mice
and 5 immunized mice per group were harvested for real-time PCR low-
density array analysis. GraphPad Prism 5.0 (GraphPad software Inc.) was
used to determine statistical significance.
Intracerebral LPS Injection and Histology
Wild-type, AcP-deficient, and AcPb-deficient mice (approximately 10 weeks
old) were acclimated to standard laboratory conditions at the CHUL Research
Center (14 hr light, 10 hr dark cycle) with free access to rodent chow andwater.
Isofluorane was used to anesthetize themice and the site for LPS injection was
stereotaxically determined by microscopy. To reach the injection site, the
coordinates from the bregma were 2 mm lateral and 3 mm dorsoventral.
1 ml of 0.9% NaCl solution or LPS (1.0 mg/ml) was injected for a period of 1
min via a microinjection pump (Razel Scientific Instruments, Stanford, CT).
1, 3, and 7 days later, mice were deeply anesthetized by i.p injection of a ket-
amine hydrochloride (91 mg/ml) and xylazine (9.1 mg/ml) solution. They were
quickly transcardially perfused with a 0.9% saline solution followed by 4%
paraformaldehyde/3.8% Borax solution (pH 9) at 4C. Immediately after fixa-
tion, brains were removed from the skulls and post-fixed in 4% paraformalde-
hyde/3.8% Borax solution (pH 9) for 24 hr. After post-fixation, brains were
placed overnight in a solution of 4% paraformaldehyde/3.8% Borax solution
(pH 9) containing 10% sucrose. The brains were mounted on a microtome
(Reichert-Jung, Cambridge Instruments Company, Deerfield, IL), frozen with
dry ice, and sliced into 25 mm coronal sections from olfactory bulb to the
end of the medulla. The obtained slices were placed in a cold cryoprotectant
solution (0.5 M sodium phosphate buffer [pH 7.3], 30% ethylene glycol, 20%
glycerol) and stored at 20C. IL-1b and Proteolipid protein (PLP) mRNA
expression was detected via in situ hybridization (ISH) as previously described
(Laflamme et al., 1999) and neuronal cell death was characterized by Fluoro-
Jade B (FJB) method (Nadeau and Rivest, 2003).
ACCESSION NUMBERS
The sequence for human AcPb has been deposited at GenBank (accession
number FJ998418) and the sequence for mouse AcPb is identical toNM_001159318 (annotated as interleukin 1 receptor accessory protein,
transcript variant 4). Microarray data are available as .CEL files at GEO under
accession number GSE16104.
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